Print page |
E-mail page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
BALTIMORE, Mar 23, 2007 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (Nasdaq:OSIR) today announced that six-month results from a clinical trial evaluating PROVACEL(TM), an adult mesenchymal stem cell (MSC) therapy for the treatment of heart disease, will be presented on Sunday, March 25.
Six-month data from the 53-patient, double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of the intravenous administration of PROVACEL to heart attack patients will be presented at 11 a.m. CT Sunday at the American College of Cardiology's Innovation in Intervention: i2Summit in New Orleans. The presenter will be Joshua Hare M.D., the trial's lead investigator and the Lemberg Professor of Medicine at the Miller School of Medicine, University of Miami; Chief of the Cardiology Division; and Director of the School's Interdisciplinary Stem Cell Institute. Osiris will issue a news release at that time announcing the results.
In addition, Osiris has scheduled a web cast and conference call to discuss the results on Monday, March 26, at 9:00 AM ET. To access the web cast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm. Alternatively, callers may participate in the conference call by dialing 800-810-0924 (U.S. participants) or 913-981-4900 (international participants).
A replay of the conference call will be available approximately three hours after the completion of the call through April 2, 2007. Callers can access the replay by dialing 888-203-1112 (U.S. participants) or 719-457-0820 (international participants). The audio replay passcode is 1463423. To access a replay of the webcast, visit the Investor Relations section of the company's website at http://investor.osiris.com/events.cfm.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells OSTEOCEL(R) for regenerating bone in orthopedic indications. PROCHYMAL(TM) is in Phase III clinical trials and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. The company's pipeline of internally developed biologic drug candidates under evaluation also includes CHONDROGEN(TM) for regenerating cartilage in the knee, and PROVACEL(TM), for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company's technology in the United States and a number of foreign countries including 47 U.S. and 167 foreign patents owned or licensed. More information can be found on the company's website, www.Osiris.com. (OSIR-G)
Forward-Looking Statements
This press release may contain forward-looking statements. These forward- looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.
SOURCE: Osiris Therapeutics, Inc.
Osiris Therapeutics Inc. Abe Wischnia, 619-871-7133 or Erica Elchin, 410-522-5005, extension 610
Copyright Business Wire 2007
News Provided by COMTEX